Financial Performance - The group recorded revenue of SGD 2.8 million for the three months ended March 31, 2019, representing an increase of approximately 10.5% compared to SGD 2.6 million for the same period in 2018[6]. - The net profit for the period was approximately SGD 0.3 million, unchanged from the previous year, primarily due to increased employee and operating expenses offsetting revenue growth[6]. - The group reported a gross profit of SGD 323,000 for the period, slightly up from SGD 307,000 in the previous year[9]. - Total comprehensive income attributable to owners of the company for the period was SGD 268,000, compared to SGD 255,000 in the previous year[9]. - Revenue increased by approximately SGD 0.3 million or 10.5% year-on-year, reaching about SGD 2.8 million for the quarter ended March 31, 2019[31]. - Net profit attributable to owners was approximately SGD 0.3 million, consistent with the same period last year[35]. - Earnings per share decreased to 0.05 Singapore cents from 0.06 Singapore cents year-on-year, with issued shares increasing from 390 million to 520 million[25]. Expenses and Costs - Employee benefits expenses increased to SGD 916,000 from SGD 713,000 in the previous year, reflecting higher operational costs[9]. - Employee benefits expenses rose by approximately SGD 0.2 million or 28.5% to about SGD 0.9 million, primarily due to hiring for new treatment centers[33]. - Other operating expenses increased by approximately SGD 0.3 million, attributed to higher marketing and legal costs post-IPO[34]. Dividends and Equity - The company did not declare any dividends for the period, consistent with the previous year[7]. - The company has no bank borrowings and maintains a strong liquidity position with no significant contingent liabilities[39][43]. - The company’s total equity as of March 31, 2019, was SGD 12.84 million, an increase from SGD 12.57 million at the beginning of the year[11]. - No dividends were declared for the period, consistent with the previous year[36]. Business Operations and Expansion - Medical services revenue included SGD 1.7 million from treatment services, SGD 0.9 million from medical examination services, and SGD 0.3 million from consultation services[19]. - The company opened two new treatment centers during the period, expanding its network under the "Dr. Tan & Partners" brand[27]. - The group continues to focus on expanding its healthcare services in Singapore, leveraging its existing facilities and expertise[14]. Compliance and Governance - The financial statements were prepared in accordance with International Financial Reporting Standards and GEM listing rules, ensuring compliance and transparency[15]. - The company has complied with all applicable corporate governance codes as per GEM Listing Rules[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements and found them compliant with applicable accounting standards[65]. - There were no interests held by directors or controlling shareholders in any competing businesses during the reporting period[58]. Shareholding Structure - As of March 31, 2019, the company had a total of 520,000,000 shares issued[52]. - Dr. Chen holds 390,000,000 shares, representing 75% of the company's issued shares[56]. - Cher Sen Holdings Limited, controlled by Dr. Chen, owns 390,000,000 shares, also accounting for 75% of the issued shares[56]. - Dr. Chen is the beneficial owner of 50,000 shares in Cher Sen, representing 100% of that entity[53]. - No other entities, apart from those disclosed, held any significant interests in the company's shares as of March 31, 2019[57]. Other Information - The company has not disclosed any new product developments or market expansions in the provided documents[64]. - No securities were repurchased or sold by the company during the reporting period[63]. - The management emphasizes ongoing investment in technology to maintain competitive advantages, particularly in the medical aesthetics sector[28].
REPUBLIC HC(08357) - 2019 Q1 - 季度财报